Pavkovic Mira, Riefke Björn, Frisk Anna-Lena, Gröticke Ina, Ellinger-Ziegelbauer Heidrun
*Investigational Toxicology, GDD-GED-Toxicology, Bayer Pharma AG, 42096 Wuppertal, Germany, Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, 02115 Boston, Massachusetts, Pathology, GDD-GED-Toxicology, Bayer Pharma AG, 13353 Berlin, Germany and Indication Expansion, GDD-GTRG-Cross Indication Platform, Bayer Pharma AG, 13353 Berlin, Germany *Investigational Toxicology, GDD-GED-Toxicology, Bayer Pharma AG, 42096 Wuppertal, Germany, Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, 02115 Boston, Massachusetts, Pathology, GDD-GED-Toxicology, Bayer Pharma AG, 13353 Berlin, Germany and Indication Expansion, GDD-GTRG-Cross Indication Platform, Bayer Pharma AG, 13353 Berlin, Germany.
*Investigational Toxicology, GDD-GED-Toxicology, Bayer Pharma AG, 42096 Wuppertal, Germany, Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, 02115 Boston, Massachusetts, Pathology, GDD-GED-Toxicology, Bayer Pharma AG, 13353 Berlin, Germany and Indication Expansion, GDD-GTRG-Cross Indication Platform, Bayer Pharma AG, 13353 Berlin, Germany.
Toxicol Sci. 2015 Jun;145(2):348-59. doi: 10.1093/toxsci/kfv053. Epub 2015 Mar 9.
MicroRNAs (miRNAs) regulate gene expression post-transcriptionally and thus are involved in various physiological and pathological states. Due to their stability in biofluids miRNAs have also been proposed as biomarkers (BMs) for tissue injury. We investigated the usefulness of urinary miRNAs for detection of site-specific renal damage in an antiglomerular basement membrane glomerulonephritis (GN) model in rats by comparing GN-induced urinary miRNAs profiles to traditional and newer protein BMs, and to proximal tubular injury-induced urinary miRNA profiles observed previously after cisplatin (Cp) treatment. Male Wistar Kyoto and Sprague Dawley rats were dosed once with 1, 2.5, and 5 ml/kg nephrotoxic serum (NTS) or 1.5 and 5 ml/kg NTS, respectively. GN and tubular damage were observed histopathologically in all treated rats after 14 days. Although serum creatinine and BUN were not changed, several protein BMs and 74 urinary miRNAs were found to be increased 8 and 14 days after NTS administration. Of these 74 miRNAs, 5 were identified as increased after NTS but not after Cp treatment. Using in situ hybridization two of them, miR-10 b and -100, were found to be localized in distal segments of the nephron, potentially reflecting the tubular injury in those regions. Furthermore, evaluation of both miRNA and mRNA expression in the kidney revealed possible miRNA-mRNA interactions mostly associated with fibrotic and transforming growth factor β signaling. In conclusion, our investigations support the potential of urinary miRNAs as specific BMs for kidney injury, and suggest a role of miRNAs in pathological processes during GN in the kidney.
微小RNA(miRNA)在转录后水平调控基因表达,因此参与多种生理和病理状态。由于其在生物流体中的稳定性,miRNA也被提议作为组织损伤的生物标志物(BM)。我们通过比较肾小球肾炎(GN)诱导的大鼠尿液miRNA谱与传统和新型蛋白质BM,以及与先前顺铂(Cp)治疗后观察到的近端肾小管损伤诱导的尿液miRNA谱,研究了尿液miRNA在大鼠抗肾小球基底膜肾小球肾炎(GN)模型中检测位点特异性肾损伤的实用性。雄性Wistar Kyoto和Sprague Dawley大鼠分别一次性给予1、2.5和5 ml/kg肾毒性血清(NTS)或1.5和5 ml/kg NTS。14天后在所有处理的大鼠中通过组织病理学观察到GN和肾小管损伤。尽管血清肌酐和尿素氮没有变化,但在NTS给药后8天和14天发现几种蛋白质BM和74种尿液miRNA增加。在这74种miRNA中,有5种被鉴定为在NTS给药后增加,但在Cp治疗后未增加。使用原位杂交发现其中两种miR-10 b和-100定位于肾单位的远端节段,可能反映了这些区域的肾小管损伤。此外,对肾脏中miRNA和mRNA表达的评估揭示了可能的miRNA-mRNA相互作用,主要与纤维化和转化生长因子β信号传导相关。总之,我们的研究支持尿液miRNA作为肾损伤特异性BM的潜力,并表明miRNA在肾脏GN病理过程中的作用。